Compagnie Lombard Odier SCmA Sells 3,902 Shares of AbbVie Inc. $ABBV

Compagnie Lombard Odier SCmA lessened its position in AbbVie Inc. (NYSE:ABBV) by 1.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 306,202 shares of the company’s stock after selling 3,902 shares during the period. AbbVie comprises about 0.8% of Compagnie Lombard Odier SCmA’s investment portfolio, making the stock its 28th biggest holding. Compagnie Lombard Odier SCmA’s holdings in AbbVie were worth $70,898,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the company. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie during the second quarter valued at $28,000. Financial Gravity Companies Inc. bought a new stake in AbbVie in the 2nd quarter worth about $36,000. Delos Wealth Advisors LLC purchased a new position in AbbVie in the 2nd quarter worth about $39,000. Finally, Cloud Capital Management LLC bought a new position in AbbVie during the 3rd quarter valued at about $53,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $223.00 on Tuesday. The stock has a 50-day simple moving average of $223.71 and a two-hundred day simple moving average of $220.07. The firm has a market capitalization of $394.13 billion, a PE ratio of 94.49, a P/E/G ratio of 0.85 and a beta of 0.35. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.